🏢 官网IRLUNGDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:05:15(美东 10-13 16:05)·⟳ 抓取 04:07:03回填·⚡ 决策 10-14 04:07:42 +2m27s·14.1 天前
Pulmonx宣布将于10月27日盘后发布2026年三季报，仅为财报日期预告
这是一份纯财报日历/日期预告稿，全文无任何业绩数字、指引更新、订单、产品或监管增量，市场对财报日期无预期差，不具备事件驱动edge；应等待10月27日实际财报再研判。
📄 原文LUNG↗ 原文
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader…
不做 Pulmonx Corporation（LUNG.US）
纯财报日期预告，无收入/利润/指引等任何增量事实或预期差，不构成方向性催化；等待2026-10-27实际财报发布后再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pulmonx仅宣布Q3财报将于10月27日盘后发布，无任何经营或财务增量，属中性例行通知，不产生交易方向，回避至实际财报。
🔎 新鲜度:最早出现 2026-10-13 · 扩散 low · price-in 风险 low ↗
关键理由
- 本稿不含收入、利润、指引等任何可重定价信息，财报日期为已知日历事件，无预期差。
主要风险
- 真正波动来自10月27日财报与指引，当前提前入场等于无信息承担事件风险。
先例如何影响了这次决策
对本次决策的影响:确认不应为本稿开仓；等待10月27日实际财报再评估。
方向:无可对照先例，且财报日期预告属纯日历事件，历史上不产生系统性方向反应，无需先例校准。
涨幅量级:无业绩增量，不存在可定价幅度。
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`pulmonx lung third quarter 2026 financial results date october 27 conference call | pulmonx q3 2026 earnings announcement schedule`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 1,644 字
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System and StratX
®
Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.pulmonx.com
.
Pulmonx
®
, Chartis
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System and StratX
®
Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.pulmonx.com
.
Pulmonx
®
, Chartis
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
742058d7c9· 2026-10-14 04:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前